Skip to content
value.today

Semma Therapeutics, Inc.

Total raised
$129 M
2 rounds on record
Latest round
$114 M
Nov 2017
First round on record
Mar 2015
Today
Acquired
Acquired by Vertex Pharmaceuticals Incorporated

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Semma Therapeutics, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Semma Therapeutics, IncVertex Pharmaceuticals Incorporated2019—$937 M—Annual report

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Semma Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$114 MNo. 2$50 to $250 million

Semma Therapeutics, Inc.: Raise no. 2, Nov 2017

Investors in this round

20 investors had bought by the notice of Feb 26, 2019: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$114 M of $120 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bastiano Sanna · Executive Officer, Director
  • Kingsley Taft · Executive Officer
  • Todd Foley · Executive Officer, Director
  • Daniel Auerbach · Director
  • Kevin Raidy · Director
  • Mark Fishman · Director
  • Mitchell Finer · Director
  • Stephen Knight · Director
  • William Sahlman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series B Preferred Stock. Total amount sold includes $13,860,712 from note conversions.”

Signed by Bastiano Sanna, Chief Executive Officer. Newest notice filed Feb 26, 2019 (1 amendment). Read the notice at the SEC.

equitySEC
Mar 2015$15 MNo. 1$10 to $50 million

Semma Therapeutics, Inc.: Raise no. 1, Mar 2015

Investors in this round

10 investors had bought by the notice of Mar 31, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $25 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kingsley Taft · Executive Officer
  • Robert Millman · Executive Officer, Director
  • Todd Foley · Executive Officer, Director
  • Jim Scopa · Director
  • Mitch Finer · Director
  • Stephen Knight · Director
  • William Sahlman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A Preferred Stock”

Signed by Robert Millman, President. Newest notice filed Mar 31, 2016 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Semma Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Semma Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Semma Therapeutics, Inc.
NameRoleNamed in
Bastiano SannaExecutive officerFeb 2019
Kingsley TaftExecutive officerFeb 2019
Todd FoleyExecutive officerFeb 2019
Elizabeth StonerExecutive officerDec 2017
Robert MillmanExecutive officerMar 2016
Bastiano SannaDirectorFeb 2019
Daniel AuerbachDirectorFeb 2019
Kevin RaidyDirectorFeb 2019
Mark FishmanDirectorFeb 2019
Mitchell FinerDirectorFeb 2019
Stephen KnightDirectorFeb 2019
Todd FoleyDirectorFeb 2019
William SahlmanDirectorFeb 2019
Jim ScopaDirectorMar 2016
Mitch FinerDirectorMar 2016
Robert MillmanDirectorMar 2016

Acquired (Jan 1, 2019). Acquired by Vertex Pharmaceuticals Incorporated.